

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Efficacy of carbapenems and alternative antimicrobials for treating complicated urinary tract infections caused by antimicrobial-resistant Gram-negative bacteria: Protocol for a systematic review and meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-069166
Article Type:	Protocol
Date Submitted by the Author:	13-Oct-2022
Complete List of Authors:	Maeda, Masayuki; Showa University, Department of Clinical Pharmacy Hasegawa, Takeshi; Showa University Noma, Hisashi; The Institute of Statistical Mathematics, Department of Data Science Ota, Erika; St Luke's International University; Tokyo Foundation for Policy Research
Keywords:	Urinary tract infections < UROLOGY, INFECTIOUS DISEASES, Pyelonephritis < NEPHROLOGY

SCHOLARONE™
Manuscripts

1
2
3
4
5
6 Efficacy of carbapenems and alternative antimicrobials for treating complicated urinary
7 tract infections caused by antimicrobial-resistant Gram-negative bacteria: Protocol for a
8 systematic review and meta-analysis
9

10
11 Masayuki Maeda^{1*}, Takeshi Hasegawa², Hisashi Noma³, Erika Ota^{4,5}
12
13

14
15 1 Division of Infection Control Sciences, Department of Clinical Pharmacy, School of
16 Pharmacy, Showa University, Tokyo, Japan; m-maeda@pharm.showa-u.ac.jp

17
18 2 Showa University Research Administration Center, Showa University, Tokyo, Japan;
19 tahasegawa@med.showa-u.ac.jp

20
21 3 Department of Data Science, The Institute of Statistical Mathematics, Tokyo, Japan;
22 noma@ism.ac.jp

23
24 4 Global Health Nursing, Graduate School of Nursing Science, St. Luke's International
25 University, Tokyo, Japan; ota@slcn.ac.jp

26
27 5 The Tokyo Foundation for Policy Research, Tokyo, Japan
28

29
30 *Corresponding author: m-maeda@pharm.showa-u.ac.jp
31

32 **ABSTRACT**

33 **Introduction**

34
35 Complicated urinary tract infections (cUTIs) are associated with poor prognosis. The
36 widespread infection of multidrug-resistant Gram-negative uropathogens such as
37 extended-spectrum beta-lactamase (ESBL)-producing bacteria has limited the efficacy of
38 antibiotics used for treating cUTI. Considering the existence of antimicrobial-resistant
39 (AMR) uropathogens, carbapenem is the last-resort antibiotic for cUTI. Given that
40 carbapenem overuse has facilitated the spread of carbapenem-resistant Gram-negative
41 bacteria, carbapenem dependence should be urgently reduced. However, improvement on
42 the clinical outcomes of alternative antibiotics against cUTI caused by AMR
43 uropathogens has not yet been systematically evaluated. Thus, this systematic review and
44 meta-analysis aims to explore and compare the clinical outcomes of cUTI caused by AMR
45 uropathogens between carbapenem and noncarbapenem antibiotics.
46
47
48
49
50
51

52 **Methods and analysis**

53
54 The study inclusion criteria will be considered based on the PICO model. P (population):
55 adult patients with cUTIs caused by Gram-negative uropathogens; I (intervention):
56 noncarbapenem class of antimicrobial agents with in vitro activities against Gram-
57 negative uropathogens; C (comparison): treatment of carbapenem class antibiotics; O
58
59
60

(outcome): clinical and microbiologic cure. Relevant articles published until December 2022 will be systematically searched in February 2023, using electronic databases such as PubMed, the Cochrane Library, EMBASE, and ClinicalTrials.gov. Two independent reviewers will screen the select literature and then assess the full-text article to meet the inclusion criteria. The risk of bias will be assessed using the Cochrane risk-of-bias assessment tool. The treatment effects of antibiotics will be estimated as a risk ratio with a 95% confidence interval, using the random-effects model.

Ethics and dissemination

This protocol and systematic review will not include direct patient data; thus, informed consent will be waived. The results of this study will be published in an international peer-reviewed journal for wider information dissemination.

PROSPERO registration number: CRD42022356064

Keywords: complicated urinary tract infection, carbapenem, antimicrobial resistant

Word Count: 1269

Strengths and limitations of this study

This new protocol will evaluate the effectiveness of carbapenem and alternative antibiotics against cUTI caused by antimicrobial-resistant (AMR) uropathogens.

The analysis of efficacy of carbapenems and alternative antibiotics will contribute to both improving patient outcomes and developing treatment strategies that are effective for cUTIs caused by AMR uropathogens.

The protocol method is conducted robustly in accordance with the Cochrane Handbook for Systematic Reviews.

Given that the inclusion criteria will include articles published and uploaded to the database, studies such as those in conference presentations and not written in English may be missed.

INTRODUCTION

Complicated urinary tract infections (cUTIs) are associated with morbidity, mortality, and excessive healthcare costs.¹⁻⁴ Guidelines for cUTIs recommend that the empirical treatment should target Gram-negative uropathogens, including *Escherichia coli*, *Klebsiella pneumoniae*, and non-Enterobacterales. Therefore, broad-spectrum antibiotics are frequently selected for empirical treatment.⁵

1
2
3
4
5
6 Over the past few decades, the widespread use of multidrug-resistant Gram-negative
7 bacteria have been limiting the efficacy of antibiotics in cUTI treatment.⁶ In particular,
8 the burden of a disease caused by extended-spectrum beta-lactamase (ESBL)-producing
9 bacteria, which have become resistant to almost all beta-lactam antibiotics, is alarming.⁷
10 Carbapenems as a representative of beta-lactam antibiotics exhibit an in vitro activity
11 against most of the Gram-negative bacteria, including AMR uropathogens such as the
12 ESBL-producing bacteria. In fact, carbapenem is the last-resort antibiotic for cUTI
13 caused by antimicrobial-resistant (AMR) uropathogens, including ESBL-producing *E.*
14 *coli* and *K. pneumoniae*.⁸ Consequently, carbapenems have been increasingly used, but
15 their widespread use has facilitated the proliferation of carbapenem-resistant Gram-
16 negative bacteria.⁹ The global spread of carbapenem-resistant bacteria reinforces the
17 urgent need to reduce carbapenem dependence. An important strategy to reduce
18 carbapenem overuse is to evaluate alternative antibiotics.¹⁰ Several systematic reviews
19 and meta-analyses were conducted to evaluate and compare the efficacy between
20 carbapenems and alternative antibiotics for the treatment of cUTIs.¹¹⁻¹⁴ The study results
21 consistently indicated that the efficacy of alternative antibiotics was noninferior to that
22 of carbapenem in patients with cUTIs. Nevertheless, the population of these meta-
23 analyses included both resistant and nonresistant strains. Considering that various
24 antibiotics can treat cUTI caused by nonresistant bacteria, focusing on resistant bacteria
25 is needed to evaluate the efficacy of carbapenem and its alternative antibiotics.
26 Presently, specific data on the efficacy of alternative antibiotics for cUTIs caused by
27 AMR uropathogens remain unavailable. In addition, improvement of the clinical
28 outcomes of patients taking alternative antibiotics for cUTI caused by AMR
29 uropathogens has not yet been systematically evaluated. Thus, we would like to conduct
30 a systematic review and meta-analysis of the clinical outcomes of cUTI caused by AMR
31 uropathogens between carbapenem and noncarbapenem antibiotics. Our meta-analysis
32 will provide useful information for the proper selection of antibiotics used for treating
33 cUTI in a clinical setting, as well as a future direction for the development of alternative
34 antibiotics for AMR cUTI.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56

57 **METHODS AND ANALYSIS**

58 This protocol adheres to the Preferred Reporting Items for Systematic review and Meta-
59
60

1
2
3
4
5
6 Analysis Protocols (PRISMA-P) guidelines. We prepared this protocol manuscript
7 according to the PRISMA-P checklist.¹⁵
8
9

10 **Population**

11 For the study population, we will include adult patients with cUTIs, including acute
12 pyelonephritis, caused by Gram-negative uropathogens that are resistant to third-
13 generation cephalosporin.¹⁶
14
15
16

17 **Interventions**

18 The intervention involves the noncarbapenem class of antimicrobial agents with in vitro
19 activities against Gram-negative uropathogens that are resistant to third-generation
20 cephalosporin.
21
22
23
24

25 **Controls**

26 The control is the treatment of carbapenem class antibiotics.
27
28
29

30 **Outcomes**

31 The primary outcome will be the composite outcome of clinical and microbiologic cure
32 defined by the US Food and Drug Administration as follows: resolution of cUTI
33 symptoms present at trial entry (and no new symptoms) and the reduction of bacterial
34 pathogens found at trial entry to fewer than 10³ CFU/mL on urine culture.¹⁷ The
35 secondary outcomes will be the microbiologic outcome responses and death at each
36 endpoint.
37
38
39
40

41 **Study designs**

42 This review will only include individual and cluster randomized controlled trials.
43
44
45

46 **Search strategy**

47 Literature published until December 2022 will be searched in February 2023 in the
48 following databases: MEDLINE/PubMed, the Cochrane Library (Cochrane Central
49 Register of Controlled Trials, CENTRAL), EMBASE, and ClinicalTrials.gov. The
50 systematic search strategy will be mainly done in MEDLINE/PubMed and the Cochrane
51 Library database. The comprehensive search strategies will use the developed search
52 terms shown in Table 1.
53
54
55
56
57
58
59
60

Table 1 Search strategy methods in PubMed

No.	Search queries
#1	Urinary Tract Infections[mh] OR "urinary tract infection*" [tiab] OR cUTI* [tiab] OR Pyelonephritis[mh] OR pyelonephritis* [tiab]
#2	Drug Resistance[mh] OR resistan* [tiab]
#3	Carbapenems[mh] OR carbapenem* [tw] OR CS-533[tw] OR CS533[tw] OR Imipenem[mh] OR imipenem* [tw] OR MK-0787[tw] OR MK0787[tw] OR N-Formimidoylthienamycin[tw] OR doripenem* [tw] OR "S 4661" [tw] OR S4661[tw] OR ertapenem* [tw] OR invanz[tw] OR panipenem* [tw] OR meropenem* [tw] OR merrem[tw] OR penem[tw] OR ronem[tw] OR SM-7338[tw] OR SM7338[tw] OR biapenem* [tw] OR L-627[tw] OR L627[tw] OR LJC-10627[tw] OR LJC10627[tw]
#4	#1 AND #2 AND #3
#5	(controlled clinical trial[pt] OR randomized [tiab] OR randomised [tiab] OR randomly [tiab] OR clinical trials as topic [mesh:noexp] OR trial [ti] OR placebo [tiab]) NOT (Animals [mh] NOT Humans [mh])
#6	#4 AND #5
#7	Sepsis [mh] OR sepsis* [tiab] OR "blood poisoning*" [tiab] OR "bloodstream Infect*" [tiab] OR pyaemi* [tiab] OR pyemi* [tiab] OR pyohemi* [tiab] OR pyohaemi* [tiab] OR septicemi* [tiab] OR "bloodstream infection*" [tiab] OR bacteremi* [tiab] OR bacteraemi* [tiab]
#8	#6 AND #7

Screening of the retrieved articles

Independent researchers will review the screening search results. The title and abstract will be screened and scrutinized to meet the study criteria, using the reference management software Rayyan.¹⁸ If they differ in decision on whether or not the study meets the inclusion criteria, another reviewer will do the screening.

Data extraction

The selected data will be extracted using Microsoft Excel, conforming to guidelines of the Cochrane Handbook for Systematic Reviews.¹⁹ The following data will be extracted from the selected studies: author names, publication year, study population, baseline characteristics, study settings, intervention details, outcomes, and subgroup analysis stratified by AMR pathogens.

Assessment of risk of bias

Independent researchers will assess the risk of bias by using the Cochrane risk-of-bias assessment tool. The assessment domain consists of the following: random sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment of self-reported outcomes and reaction time (detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias), and other biases, such as imbalance of baseline characteristics and overdiagnosis bias.²⁰ The included studies will be divided into low risk, high risk, and unclear risk according to the reviewers' judgment. Any discord will be resolved through a discussion between them.

Data analysis

For dichotomous data, the treatment effects will be estimated as a risk ratio with a 95% confidence interval, using the random effects model. Heterogeneity will be assessed using the chi-square test and I^2 statistics. The heterogeneity will be addressed through meta-regression and subgroup analyses. Publication bias will be assessed in forest plots using Egger's test. Forest plots and funnel plots will be generated using the Review Manager (RevMan) software.

Grading of evidence

The strength of the body of evidence will be assessed using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) to judge the quality of evidence for outcomes. GRADE will then be assessed according to the risk of bias among studies, inconsistency, imprecision, indirectness, and publication bias.

Patient and public involvement

No patients or citizens will be involved in this research. Only data that are already published will be used. For this systematic review, the estimation of the efficacy of the treatment will benefit patients with cUTI.

ETHICS AND DISSEMINATION

This meta-analysis will not include direct patient data because it will only use studies that are already published. Therefore, informed consent will be waived. The results of this study will be published in an international peer-reviewed journal for wider information dissemination. This work will influence the national guidelines for the treatment of

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

cUTIs.¹⁶

Contributorship statement:

Conception of the study: MM. Statistical concept: TH, HN, and EO. Construction of search strategy: MM. Drafting manuscript: MM and TH. Review and finalization: TH, HN, and EO. All authors reviewed and approved the final version of the manuscript. Guarantor of the review: MM.

Funding statement:

This work was supported by JSPS KAKENHI Grant Number 19K03092.

Competing interests statement

None declared.

Patient and public involvement

Patients and the public were not involved in the design, or conduct, or reporting, or dissemination plans of this protocol.

Patient consent for publication

Not applicable

Provenance and peer review

Not commissioned; externally peer reviewed.

REFERENCES

1. Nicolle LE; AMMI Canada Guidelines Committee. Complicated urinary tract infection in adults. *Can J Infect Dis Med Microbiol.* 2005;16(6):349.
2. Wagenlehner FME, Bjerklund Johansen TE, Cai T, Koves B, Kranz J, Pilatz A, Tandogdu Z. Epidemiology, definition and treatment of complicated urinary tract infections. *Nat Rev Urol.* 2020;17(10):586.
3. Brown P, Ki M, Foxman B. Acute pyelonephritis among adults: cost of illness and considerations for the economic evaluation of therapy. *Pharmacoeconomics.* 2005;23(11):1123.
4. Neal DE Jr. Complicated urinary tract infections. *Urol Clin North Am.* 2008;35(1):13.

5. Hooton TM, Bradley SF, Cardenas DD, Colgan R, Geerlings SE, Rice JC, Saint S, Schaeffer AJ, Tambayh PA, Tenke P, Nicolle LE; Infectious Diseases Society of America. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. *Clin Infect Dis*. 2010;50(5):625.
6. World Health Organization. Antimicrobial resistance. Available from: <https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance>. Accessed June 6, 2022.
7. Bezabih YM, Bezabih A, Dion M, Batard E, Teka S, Obbole A, Dessalegn N, Enyew A, Roujeinikova A, Alamneh E, Mirkazemi C, Peterson GM, Bezabhe WM. Comparison of the global prevalence and trend of human intestinal carriage of ESBL-producing *Escherichia coli* between healthcare and community settings: a systematic review and meta-analysis. *JAC Antimicrob Resist*. 2022;4(3):dlac048.
8. Paterson DL, Henderson A, Harris PNA. Current evidence for therapy of ceftriaxone-resistant Gram-negative bacteremia. *Curr Opin Infect Dis*. 2020;33(1):78.
9. European Centre for Disease Prevention and Control. Carbapenem-resistant Enterobacteriaceae (CRE). Available from: <https://www.ecdc.europa.eu/en/publications-data/directory-guidance-prevention-and-control/prevention-and-control-infections-1>. Accessed June 6, 2022.
10. Wilson APR. Sparing carbapenem usage. *J Antimicrob Chemother*. 2017;72(9):2410.
11. Singh KP, Li G, Mitrani-Gold FS, Kurtinecz M, Wetherington J, Tomayko JF, Mundy LM. Systematic review and meta-analysis of antimicrobial treatment effect estimation in complicated urinary tract infection. *Antimicrob Agents Chemother*. 2013;57(11):5284.
12. Ten Doesschate T, van der Vaart TW, Damen JAA, Bonten MJM, van Werkhoven CH. Carbapenem-alternative strategies for complicated urinary tract infections: A systematic review of randomized controlled trials. *J Infect*. 2020;81(4):499.
13. Isler B, Ezure Y, Romero JLG, Harris P, Stewart AG, Paterson DL. Is ceftazidime/avibactam an option for serious infections due to extended-spectrum- β -lactamase- and AmpC-producing enterobacterales?: A systematic review and meta-analysis. *Antimicrob Agents Chemother*. 2020;65(1):e01052-20.

14. Ezure Y, Rico V, Paterson DL, Hall L, Harris PNA, Soriano A, Roberts JA, Bassetti M, Roberts MJ, Righi E, Wright H. Efficacy and safety of carbapenems vs new antibiotics for treatment of adult patients with complicated urinary tract infections: A systematic review and meta-analysis. *Open Forum Infect Dis*. 2022;9(5):ofaa480.
15. Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA; PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ*. 2015;350:g7647.
16. Infectious Diseases Society of America. IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections: Version 1.0. Available: <https://www.idsociety.org/practice-guideline/amr-guidance/>
17. U.S. Food & Drug Administration. Complicated urinary tract infections: developing drugs for treatment. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Available: <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/complicated-urinary-tract-infections-developing-drugs-treatment>
18. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. *Syst Rev*. 2016;5(1):210.
19. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). *Cochrane Handbook for Systematic Reviews of Interventions* version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.
20. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, Norris S, Falck-Ytter Y, Glasziou P, DeBeer H, Jaeschke R, Rind D, Meerpohl J, Dahm P, Schünemann HJ. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. *J Clin Epidemiol*. 2011;64(4):383

Reporting checklist for protocol of a systematic review and meta analysis.

Based on the PRISMA-P guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the PRISMA-Reporting guidelines, and cite them as:

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.

			Page Number
Title			
Identification	#1a	Identify the report as a protocol of a systematic review	1
Update	#1b	If the protocol is for an update of a previous systematic review, identify as such	n/a

1 Registration

2
3
4 [#2](#) If registered, provide the name of the registry (such as 2
5
6 PROSPERO) and registration number
7
8

9 Authors

10
11
12
13 Contact [#3a](#) Provide name, institutional affiliation, e-mail address of all 1
14
15 protocol authors; provide physical mailing address of
16
17 corresponding author
18

19
20 Contribution [#3b](#) Describe contributions of protocol authors and identify the 7
21
22 guarantor of the review
23
24

25 Amendments

26
27
28
29 [#4](#) If the protocol represents an amendment of a previously 2
30
31 completed or published protocol, identify as such and list
32
33 changes; otherwise, state plan for documenting important
34
35 protocol amendments
36
37

38 Support

39
40
41
42 Sources [#5a](#) Indicate sources of financial or other support for the review 7
43

44
45 Sponsor [#5b](#) Provide name for the review funder and / or sponsor 7
46

47
48 Role of sponsor or [#5c](#) Describe roles of funder(s), sponsor(s), and / or institution(s), 7
49
50 funder
51 if any, in developing the protocol
52

53 Introduction

54
55
56 Rationale [#6](#) Describe the rationale for the review in the context of what is 2,3
57
58

1		already known	
2			
3			
4	Objectives	#7 Provide an explicit statement of the question(s) the review will	3,4
5		address with reference to participants, interventions,	
6		comparators, and outcomes (PICO)	
7			
8			
9			
10			
11	Methods		
12			
13			
14	Eligibility criteria	#8 Specify the study characteristics (such as PICO, study design,	3,4
15		setting, time frame) and report characteristics (such as years	
16		considered, language, publication status) to be used as	
17		criteria for eligibility for the review	
18			
19			
20			
21			
22			
23			
24	Information	#9 Describe all intended information sources (such as electronic	4
25		databases, contact with study authors, trial registers or other	
26	sources	grey literature sources) with planned dates of coverage	
27			
28			
29			
30			
31			
32	Search strategy	#10 Present draft of search strategy to be used for at least one	4
33		electronic database, including planned limits, such that it	
34		could be repeated	
35			
36			
37			
38			
39	Study records -	#11a Describe the mechanism(s) that will be used to manage	5
40		records and data throughout the review	
41	data management		
42			
43			
44			
45	Study records -	#11b State the process that will be used for selecting studies (such	5
46		as two independent reviewers) through each phase of the	
47	selection process	review (that is, screening, eligibility and inclusion in meta-	
48		analysis)	
49			
50			
51			
52			
53			
54	Study records -	#11c Describe planned method of extracting data from reports	5
55		(such as piloting forms, done independently, in duplicate), any	
56	data collection		
57			
58			
59			
60			

1	process		processes for obtaining and confirming data from investigators	
2				
3				
4	Data items	#12	List and define all variables for which data will be sought	3,4
5			(such as PICO items, funding sources), any pre-planned data	
6			assumptions and simplifications	
7				
8				
9				
10				
11	Outcomes and	#13	List and define all outcomes for which data will be sought,	3,4
12				
13	prioritization		including prioritization of main and additional outcomes, with	
14			rationale	
15				
16				
17				
18				
19	Risk of bias in	#14	Describe anticipated methods for assessing risk of bias of	6
20				
21	individual studies		individual studies, including whether this will be done at the	
22			outcome or study level, or both; state how this information will	
23			be used in data synthesis	
24				
25				
26				
27				
28				
29	Data synthesis	#15a	Describe criteria under which study data will be quantitatively	6
30			synthesised	
31				
32				
33				
34	Data synthesis	#15b	If data are appropriate for quantitative synthesis, describe	6
35			planned summary measures, methods of handling data and	
36			methods of combining data from studies, including any	
37			planned exploration of consistency (such as I ² , Kendall's τ)	
38				
39				
40				
41				
42				
43				
44	Data synthesis	#15c	Describe any proposed additional analyses (such as	6
45			sensitivity or subgroup analyses, meta-regression)	
46				
47				
48				
49	Data synthesis	#15d	If quantitative synthesis is not appropriate, describe the type	6
50			of summary planned	
51				
52				
53				
54	Meta-bias(es)	#16	Specify any planned assessment of meta-bias(es) (such as	6
55			publication bias across studies, selective reporting within	
56				
57				
58				
59				
60				

studies)

Confidence in [#17](#) Describe how the strength of the body of evidence will be
cumulative assessed (such as GRADE)
evidence

6

The PRISMA-P elaboration and explanation paper is distributed under the terms of the Creative Commons Attribution License CC-BY. This checklist was completed on 12. October 2022 using <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)

BMJ Open

Efficacy of carbapenems versus alternative antimicrobials for treating complicated urinary tract infections caused by antimicrobial-resistant Gram-negative bacteria: Protocol for a systematic review and meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-069166.R1
Article Type:	Protocol
Date Submitted by the Author:	23-Jan-2023
Complete List of Authors:	Maeda, Masayuki; Showa University, Department of Clinical Pharmacy Hasegawa, Takeshi; Showa University Noma, Hisashi; The Institute of Statistical Mathematics, Department of Data Science Ota, Erika; St Luke's International University; Tokyo Foundation for Policy Research
Primary Subject Heading:	Infectious diseases
Secondary Subject Heading:	Urology
Keywords:	Urinary tract infections < UROLOGY, INFECTIOUS DISEASES, Pyelonephritis < NEPHROLOGY

SCHOLARONE™
Manuscripts

1
2
3
4
5
6 Efficacy of carbapenems versus alternative antimicrobials for treating complicated
7 urinary tract infections caused by antimicrobial-resistant Gram-negative bacteria:
8 Protocol for a systematic review and meta-analysis
9

10
11 Masayuki Maeda^{1*}, Takeshi Hasegawa², Hisashi Noma³, Erika Ota^{4,5}
12
13

14
15 1 Division of Infection Control Sciences, Department of Clinical Pharmacy, School of
16 Pharmacy, Showa University, Tokyo, Japan; m-maeda@pharm.showa-u.ac.jp

17
18 2 Showa University Research Administration Center, Showa University, Tokyo, Japan;
19 tahasegawa@med.showa-u.ac.jp

20
21 3 Department of Data Science, The Institute of Statistical Mathematics, Tokyo, Japan;
22 noma@ism.ac.jp

23
24 4 Global Health Nursing, Graduate School of Nursing Science, St. Luke's International
25 University, Tokyo, Japan; ota@slcn.ac.jp

26
27 5 The Tokyo Foundation for Policy Research, Tokyo, Japan
28

29
30 *Corresponding author: m-maeda@pharm.showa-u.ac.jp
31

32
33 **ABSTRACT**

34 **Introduction**

35
36 Complicated urinary tract infections (cUTIs) are associated with poor prognosis. The
37 widespread infection of multidrug-resistant Gram-negative uropathogens such as
38 extended-spectrum beta-lactamase (ESBL)-producing bacteria has limited the efficacy of
39 antibiotics used for treating cUTI. Considering the existence of antimicrobial-resistant
40 (AMR) uropathogens, carbapenem is the last-resort antibiotic for cUTI. Given that
41 carbapenem overuse has facilitated the spread of carbapenem-resistant Gram-negative
42 bacteria, carbapenem dependence should be urgently reduced. However, improvement on
43 the clinical outcomes of alternative antibiotics against cUTI caused by AMR
44 uropathogens has not yet been systematically evaluated. Thus, this systematic review and
45 meta-analysis aims to explore and compare the clinical outcomes of cUTI caused by AMR
46 uropathogens between carbapenem and noncarbapenem antibiotics.
47
48
49
50
51

52 **Methods and analysis**

53
54 The study inclusion criteria will be considered based on the PICO model consisting the
55 following elements; population: adult patients with cUTIs caused by Gram-negative
56 uropathogens; intervention: noncarbapenem class of antimicrobial agents with in vitro
57 activities against Gram-negative uropathogens; comparison: treatment of carbapenem
58
59
60

1
2
3
4
5
6 class antibiotics; outcome: a clinical and microbiologic cure. Relevant articles published
7 until December 2022 will be systematically searched in February 2023, using electronic
8 databases such as PubMed, the Cochrane Library, EMBASE, and ClinicalTrials.gov. Two
9 independent reviewers will screen the select literature and then assess the full-text article
10 to meet the inclusion criteria. The risk of bias will be assessed using the Cochrane risk-
11 of-bias assessment tool. The treatment effects of antibiotics will be estimated as a risk
12 ratio with a 95% confidence interval, using the random-effects model.
13

14 **Ethics and dissemination**

15
16 This protocol and systematic review will not include direct patient data; thus, informed
17 consent will be waived. The results of this study will be published in an international
18 peer-reviewed journal for wider information dissemination.
19

20 **PROSPERO registration number:** CRD42022356064

21 **Keywords:** complicated urinary tract infection, carbapenem, antimicrobial resistant
22

23
24
25
26
27 Word Count: 1418
28

29 **Strengths and limitations of this study**

30
31 This new protocol will evaluate the effectiveness of carbapenem and alternative
32 antibiotics against cUTI caused by antimicrobial-resistant (AMR) uropathogens.
33

34 The analysis of efficacy of carbapenems and alternative antibiotics will contribute to
35 both improving patient outcomes and developing treatment strategies that are effective
36 for cUTIs caused by AMR uropathogens.
37

38 The protocol method is conducted robustly in accordance with the Cochrane Handbook
39 for Systematic Reviews.
40

41 Given that the inclusion criteria will include articles published and uploaded to the
42 database, studies such as those in conference presentations and not written in English may
43 be missed.
44
45

46 **INTRODUCTION**

47
48 Complicated urinary tract infections (cUTIs) are associated with morbidity, mortality,
49 and excessive healthcare costs.¹⁻⁴ Guidelines for cUTIs recommend that the empirical
50 treatment should target Gram-negative uropathogens, including *Escherichia coli*,
51 *Klebsiella pneumoniae*, and non-Enterobacterales. Therefore, broad-spectrum
52 antibiotics are frequently selected for empirical treatment.⁵
53
54
55
56
57
58
59
60

1
2
3
4
5
6 Over the past few decades, the widespread use of multidrug-resistant Gram-negative
7 bacteria have been limiting the efficacy of antibiotics in cUTI treatment.⁶ In particular,
8 the burden of a disease caused by extended-spectrum beta-lactamase (ESBL)-producing
9 bacteria, which have become resistant to almost all beta-lactam antibiotics, is alarming.⁷
10 Carbapenems as a representative of beta-lactam antibiotics exhibit an in vitro activity
11 against most of the Gram-negative bacteria, including AMR uropathogens such as the
12 ESBL-producing bacteria. In fact, carbapenem is the last-resort antibiotic for cUTI
13 caused by antimicrobial-resistant (AMR) uropathogens, including ESBL-producing *E.*
14 *coli* and *K. pneumoniae*.⁸ Consequently, carbapenems have been increasingly used, but
15 their widespread use has facilitated the proliferation of carbapenem-resistant Gram-
16 negative bacteria.⁹ The global spread of carbapenem-resistant bacteria reinforces the
17 urgent need to reduce carbapenem dependence. An important strategy to reduce
18 carbapenem overuse is to evaluate alternative antibiotics.¹⁰ Several systematic reviews
19 and meta-analyses were conducted to evaluate and compare the efficacy between
20 carbapenems and alternative antibiotics for the treatment of cUTIs.¹¹⁻¹⁴ The study results
21 consistently indicated that the efficacy of alternative antibiotics was noninferior to that
22 of carbapenem in patients with cUTIs. Nevertheless, the population of these meta-
23 analyses included both resistant and nonresistant strains. Considering that various
24 antibiotics can treat cUTI caused by nonresistant bacteria, focusing on resistant bacteria
25 is needed to evaluate the efficacy of carbapenem and its alternative antibiotics.
26 Presently, specific data on the efficacy of alternative antibiotics for cUTIs caused by
27 AMR uropathogens remain unavailable. In addition, improvement of the clinical
28 outcomes of patients taking alternative antibiotics for cUTI caused by AMR
29 uropathogens has not yet been systematically evaluated. Thus, we would like to conduct
30 a systematic review and meta-analysis of the clinical outcomes of cUTI caused by AMR
31 uropathogens between carbapenem and noncarbapenem antibiotics. Our meta-analysis
32 will provide useful information for the proper selection of antibiotics used for treating
33 cUTI in a clinical setting, as well as a future direction for the development of alternative
34 antibiotics for AMR cUTI.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56

57 **METHODS AND ANALYSIS**

58 This protocol adheres to the Preferred Reporting Items for Systematic review and Meta-
59
60

1
2
3
4
5
6 Analysis Protocols (PRISMA-P) guidelines. We prepared this protocol manuscript
7 according to the PRISMA-P checklist.^{15,16}
8
9

10 **Population**

11 For the study population, we will include adult patients with cUTIs, including acute
12 pyelonephritis, caused by Gram-negative uropathogens that are resistant to third-
13 generation cephalosporin.¹⁷
14
15
16

17 **Interventions**

18 The intervention involves the noncarbapenem class of antimicrobial agents with in vitro
19 activities against Gram-negative uropathogens that are resistant to third-generation
20 cephalosporin.
21
22
23
24

25 **Controls**

26 The control is the treatment of carbapenem class antibiotics.
27
28
29

30 **Outcomes**

31 The primary outcome will be the composite outcome of clinical and microbiologic cure
32 defined by the US Food and Drug Administration as follows: resolution of cUTI
33 symptoms present at trial entry (and no new symptoms) and the reduction of bacterial
34 pathogens found at trial entry to fewer than 10³ CFU/mL on urine culture.¹⁸ The
35 secondary outcomes will be the microbiologic outcome responses and death at each
36 endpoint.
37
38
39
40

41 **Study designs**

42 This review will only include individual and cluster randomized controlled trials.
43
44
45

46 **Search strategy**

47 Literature published until December 2022 will be searched in February 2023 in the
48 following databases: MEDLINE/PubMed, the Cochrane Library (Cochrane Central
49 Register of Controlled Trials, CENTRAL), EMBASE, and ClinicalTrials.gov. The
50 comprehensive search strategies will use the developed search terms shown in Table 1
51 and Supplemental File 1.
52
53
54
55
56
57
58
59
60

Table 1 Comprehensive search strategy methods for Medline/PubMed

No.	Search queries
#1	Urinary Tract Infections[mh] OR "urinary tract infection*" [tiab] OR cUTI* [tiab] OR Pyelonephritis[mh] OR pyelonephritis* [tiab]
#2	Drug Resistance[mh] OR resistan* [tiab]
#3	Carbapenems[mh] OR carbapenem* [tw] OR CS-533[tw] OR CS533[tw] OR Imipenem[mh] OR imipenem* [tw] OR MK-0787[tw] OR MK0787[tw] OR N-Formimidoylthienamycin[tw] OR doripenem* [tw] OR "S 4661" [tw] OR S4661[tw] OR ertapenem* [tw] OR invanz[tw] OR panipenem* [tw] OR meropenem* [tw] OR merrem[tw] OR penem[tw] OR ronem[tw] OR SM-7338[tw] OR SM7338[tw] OR biapenem* [tw] OR L-627[tw] OR L627[tw] OR LJC-10627[tw] OR LJC10627[tw]
#4	#1 AND #2 AND #3
#5	(controlled clinical trial[pt] OR randomized [tiab] OR randomised [tiab] OR randomly [tiab] OR clinical trials as topic [mesh:noexp] OR trial [ti] OR placebo [tiab]) NOT (Animals [mh] NOT Humans [mh])
#6	#4 AND #5
#7	Sepsis [mh] OR sepsis* [tiab] OR "blood poisoning*" [tiab] OR "bloodstream Infect*" [tiab] OR pyaemi* [tiab] OR pyemi* [tiab] OR pyohemi* [tiab] OR pyohaemi* [tiab] OR septicemi* [tiab] OR "bloodstream infection*" [tiab] OR bacteremi* [tiab] OR bacteraemi* [tiab]
#8	#6 AND #7

Screening of the retrieved articles

Two independent researchers will screen the retrieved articles. The title and abstract will be screened and scrutinized to meet the study criteria, using the online software Rayyan, which helps to conduct systematic reviews.¹⁹ Two researchers will independently review the full-text manuscripts according to the eligibility criteria for this review. If they differ in the decision on whether or not the study meets the inclusion criteria, another reviewer will resolve the conflicts.

Data extraction

The selected data will be extracted by two independent researchers using Microsoft Excel, conforming to guidelines of the Cochrane Handbook for Systematic Reviews.²⁰ The following data will be extracted from the selected studies: author names, publication year,

1
2
3
4
5
6 study population, baseline characteristics, study settings, intervention details, outcomes,
7 and subgroup analysis stratified by AMR pathogens.
8
9

10 **Assessment of risk of bias**

11 Two independent researchers will assess the risk of bias using the Cochrane risk-of-bias
12 assessment tool. The assessment domain consists of the following: random sequence
13 generation (selection bias), allocation concealment (selection bias), blinding of
14 participants and personnel (performance bias), blinding of outcome assessment of self-
15 reported outcomes and reaction time (detection bias), incomplete outcome data (attrition
16 bias), selective reporting (reporting bias), and other biases, such as imbalance of baseline
17 characteristics and overdiagnosis bias.²¹ The included studies will be divided into low
18 risk, high risk, and unclear risk according to the reviewers' judgment. Any discord will
19 be resolved through a discussion between them.
20
21
22
23
24
25

26 **Data analysis**

27 For dichotomous data, the treatment effects will be estimated as a risk ratio with a 95%
28 confidence interval, using the random effects model. We will use the random-effects
29 model to address the possible between-studies heterogeneity. We cannot assess how
30 statistical heterogeneity exists before seeing the datasets; thus, we will adopt the random-
31 effect model for the primary statistical analyses. Heterogeneity will be assessed using the
32 chi-square test and I^2 statistics. The heterogeneity will be addressed through meta-
33 regression and subgroup analyses. We will conduct a sensitivity analysis to determine the
34 impact of the exclusion of studies at an overall high risk of bias and outliers for the
35 primary outcome. Publication bias will be assessed in forest plots using Egger's test.
36 Forest plots and funnel plots will be generated using the Review Manager (RevMan)
37 software. We will perform the synthesis analyses when at least four studies are eligible.
38 After the preliminary assessments of publication biases, we will perform the meta-
39 analyses if there are no serious systematic biases. We will present summary data and
40 assess individual studies in detail if a meta-analysis is not feasible.²⁰
41
42
43
44
45
46
47
48
49

50 **Grading of evidence**

51 The strength of the body of evidence will be assessed by two independent researchers
52 using the Grading of Recommendations, Assessment, Development and Evaluations
53 (GRADE) to judge the quality of evidence for outcomes.²² GRADE will then be assessed
54 according to the risk of bias among studies, inconsistency, imprecision, indirectness, and
55 publication bias. We will generate a summary of the findings table using the GRADEpro
56
57
58
59
60

software.

Patient and public involvement

No patients or citizens will be involved in this research. Only data that are already published will be used. For this systematic review, the estimation of the efficacy of the treatment will benefit patients with cUTI.

ETHICS AND DISSEMINATION

This systematic review and meta-analysis will not include direct patient data because it will only use studies that are already published. Therefore, informed consent will be waived. The results of this study will be published in an international peer-reviewed journal for wider information dissemination. This work will influence the national guidelines for the treatment of cUTIs.¹⁷

Contributorship statement:

Conception of the study: MM. Statistical concept: TH, HN, and EO. Construction of search strategy: MM. Drafting manuscript: MM and TH. Review and finalization: TH, HN, and EO. All authors reviewed and approved the final version of the manuscript. Guarantor of the review: MM.

Funding statement:

This work was supported by JSPS KAKENHI Grant Number 19K03092.

Competing interests statement

None declared.

Patient consent for publication

Not applicable

Provenance and peer review

Not commissioned; externally peer reviewed.

REFERENCES

1. Nicolle LE; AMMI Canada Guidelines Committee. Complicated urinary tract infection in adults. *Can J Infect Dis Med Microbiol.* 2005;16(6):349.

- 1
2
3
4
5
6 2. Wagenlehner FME, Bjerklund Johansen TE, Cai T, Koves B, Kranz J, Pilatz A,
7 Tandogdu Z. Epidemiology, definition and treatment of complicated urinary tract
8 infections. *Nat Rev Urol*. 2020;17(10):586.
- 9
10
11 3. Brown P, Ki M, Foxman B. Acute pyelonephritis among adults: cost of illness and
12 considerations for the economic evaluation of therapy. *Pharmacoeconomics*.
13 2005;23(11):1123.
- 14
15
16 4. Neal DE Jr. Complicated urinary tract infections. *Urol Clin North Am*. 2008;35(1):13.
- 17
18 5. Hooton TM, Bradley SF, Cardenas DD, Colgan R, Geerlings SE, Rice JC, Saint S,
19 Schaeffer AJ, Tambayh PA, Tenke P, Nicolle LE; Infectious Diseases Society of
20 America. Diagnosis, prevention, and treatment of catheter-associated urinary tract
21 infection in adults: 2009 International Clinical Practice Guidelines from the
22 Infectious Diseases Society of America. *Clin Infect Dis*. 2010;50(5):625.
- 23
24
25 6. World Health Organization. Antimicrobial resistance. Available from:
26 <https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance>.
27 Accessed June 6, 2022.
- 28
29
30 7. Bezabih YM, Bezabih A, Dion M, Batard E, Teka S, Obole A, Dessalegn N, Enyew
31 A, Roujeinikova A, Alamneh E, Mirkazemi C, Peterson GM, Bezabhe WM.
32 Comparison of the global prevalence and trend of human intestinal carriage of ESBL-
33 producing *Escherichia coli* between healthcare and community settings: a systematic
34 review and meta-analysis. *JAC Antimicrob Resist*. 2022;4(3):dlac048.
- 35
36
37 8. Paterson DL, Henderson A, Harris PNA. Current evidence for therapy of ceftriaxone-
38 resistant Gram-negative bacteremia. *Curr Opin Infect Dis*. 2020;33(1):78.
- 39
40
41 9. European Centre for Disease Prevention and Control. Carbapenem-resistant
42 *Enterobacteriaceae* (CRE). Available from:
43 [https://www.ecdc.europa.eu/en/publications-data/directory-guidance-prevention-](https://www.ecdc.europa.eu/en/publications-data/directory-guidance-prevention-and-control/prevention-and-control-infections-1)
44 [and-control/prevention-and-control-infections-1](https://www.ecdc.europa.eu/en/publications-data/directory-guidance-prevention-and-control/prevention-and-control-infections-1). Accessed June 6, 2022.
- 45
46
47 10. Wilson APR. Sparing carbapenem usage. *J Antimicrob Chemother*. 2017;72(9):2410.
- 48
49
50 11. Singh KP, Li G, Mitrani-Gold FS, Kurtinecz M, Wetherington J, Tomayko JF,
51 Mundy LM. Systematic review and meta-analysis of antimicrobial treatment effect
52 estimation in complicated urinary tract infection. *Antimicrob Agents Chemother*.
53 2013;57(11):5284.
- 54
55
56
57
58
59
60

12. Ten Doesschate T, van der Vaart TW, Damen JAA, Bonten MJM, van Werkhoven CH. Carbapenem-alternative strategies for complicated urinary tract infections: A systematic review of randomized controlled trials. *J Infect.* 2020;81(4):499.
13. Isler B, Ezure Y, Romero JLG, Harris P, Stewart AG, Paterson DL. Is ceftazidime/avibactam an option for serious infections due to extended-spectrum- β -lactamase- and AmpC-producing enterobacteriales?: A systematic review and meta-analysis. *Antimicrob Agents Chemother.* 2020;65(1):e01052-20.
14. Ezure Y, Rico V, Paterson DL, Hall L, Harris PNA, Soriano A, Roberts JA, Bassetti M, Roberts MJ, Righi E, Wright H. Efficacy and safety of carbapenems vs new antibiotics for treatment of adult patients with complicated urinary tract infections: A systematic review and meta-analysis. *Open Forum Infect Dis.* 2022;9(5):ofaa480.
15. Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA; PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ.* 2015;350:g7647.
16. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ.* 2021;372:n71.
17. Infectious Diseases Society of America. IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections: Version 1.0. Available: <https://www.idsociety.org/practice-guideline/amr-guidance/>
18. U.S. Food & Drug Administration. Complicated urinary tract infections: developing drugs for treatment. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Available: <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/complicated-urinary-tract-infections-developing-drugs-treatment>
19. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. *Syst Rev.* 2016;5(1):210.

- 1
2
3
4
5
6 20. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors).
7 Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated
8 February 2022). Cochrane, 2022. Available from
9 www.training.cochrane.org/handbook.
10
11
12
13 21. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, Norris S, Falck-Ytter Y,
14 Glasziou P, DeBeer H, Jaeschke R, Rind D, Meerpohl J, Dahm P, Schünemann HJ.
15 GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of
16 findings tables. *J Clin Epidemiol*. 2011;64(4):383
17
18
19 22. Schünemann HJ, Higgins JPT, Vist GE, Glasziou P, Akl EA, Skoetz N, Guyatt GH.
20 Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of
21 the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ,
22 Welch VA (editors). *Cochrane Handbook for Systematic Reviews of Interventions*
23 version 6.3 (updated February 2022). Cochrane, 2022. Available from
24 www.training.cochrane.org/handbook.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supplemental material - bmjopen-2022-069166

Table 1 Comprehensive search strategy methods for Cochrane Library (Cochrane Central Register of Controlled Trials, CENTRAL)

No.	Search queries
#1	[mh "Urinary Tract Infections"] OR [mh Pyelonephritis] OR ((urinary NEXT tract NEXT infection*) OR cUTI* OR APEKS-cUTI* OR pyelonephritis*):ti,ab,kw
#2	[mh "Drug Resistance"] OR resistan*:ti,ab,kw
#3	[mh Carbapenems] OR [mh Imipenem] OR (carbapenem* OR CS?533 OR imipenem* OR MK?0787 OR N-Formimidoylthienamycin OR doripenem* OR S?4661 OR ertapenem* OR invanz OR panipenem* OR meropenem* OR merrem OR penem OR ronem OR SM?7338 OR biapenem* OR L?627 OR LJC?10627 OR CLI?86815):ti,ab,kw
#4	#1 AND #2 AND #3
#5	[mh sepsis] OR (sepsis* OR (blood NEXT poisoning*) OR (bloodstream NEXT Infect*) OR pyaemi* OR pyemi* OR pyohemi* OR pyohaemi* OR septicemi* OR (bloodstream NEXT infection*) OR bacteremi* OR bacteraemi* OR (blood NEXT stream NEXT Infect*)):ti,ab,kw
#6	#4 AND #5

Table 2 Comprehensive search strategy methods for EMBASE.

No.	Search queries
#1	'urinary tract infection'/exp OR 'urinary tract infection' OR cuti* OR 'pyelonephritis'/exp OR pyelonephritis
#2	'drug resistance'/exp OR 'drug resistance' OR 'resistance'/exp OR resistance
#3	'carbapenems'/exp OR carbapenems OR 'cs 533'/exp OR 'cs 533' OR 'cs533'/exp OR cs533 OR 'panipenem'/exp OR panipenem OR 'imipenem'/exp OR imipenem OR 'mk 0787'/exp OR 'mk 0787' OR mk0787 OR 'n formimidoylthienamycin'/exp OR 'n formimidoylthienamycin' OR 'doripenem'/exp OR doripenem OR 's 4661'/exp OR 's 4661' OR 's4661'/exp OR s4661 OR 'ertapenem'/exp OR ertapenem OR 'invanz'/exp OR invanz OR 'meropenem'/exp OR meropenem OR 'merrem'/exp OR merrem OR penem OR ronem OR 'sm 7338'/exp OR 'sm 7338' OR 'sm7338'/exp OR sm7338 OR 'biapenem'/exp OR biapenem OR 'l 627'/exp OR 'l 627' OR 'l627'/exp OR l627 OR 'ljc 10627'/exp OR 'ljc 10627' OR 'ljc10627'/exp OR ljc10627

#4	#1 AND #2 AND #3
#5	'clinical trial'/de OR 'randomized controlled trial'/de OR 'randomization'/de OR 'single blind procedure'/de OR 'double blind procedure'/de OR 'crossover procedure'/de OR 'placebo'/de OR 'prospective study'/de OR ('randomi?ed controlled' NEXT/1 trial*) OR rct OR 'randomly allocated' OR 'allocated randomly' OR 'random allocation' OR (allocated NEAR/2 random) OR (single NEXT/1 blind*) OR (double NEXT/1 blind*) OR ((treble OR triple) NEAR/1 blind*) OR placebo*
#6	#4 AND #5
#7	'sepsis'/exp OR sepsis OR 'blood poisoning' OR 'bloodstream infection'/exp OR 'bloodstream infection' OR 'pyemia'/exp OR pyemia OR 'pyohemia'/exp OR pyohemia OR 'septicemia'/exp OR septicemia OR 'bacteremia'/exp OR bacteremia OR 'bacteraemia'/exp OR bacteraemia
#8	#6 AND #7

Table 3 Comprehensive search strategy methods for ClinicalTrials.gov.

Search fields	Search queries
Condition or disease	("Urinary Tract Infections" OR Bacteriuria OR Pyuria OR cUTI OR Pyelonephritis)
Other terms	(resistant OR resistance)
Intervention/treatment	(carbapenem OR doripenem OR ertapenem OR Imipenem OR doripenem OR ertapenem OR meropenem OR biapenem)

Reporting checklist for protocol of a systematic review and meta analysis.

Based on the PRISMA-P guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the PRISMA-Reporting guidelines, and cite them as:

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.

			Page Number
Title			
Identification	#1a	Identify the report as a protocol of a systematic review	1
Update	#1b	If the protocol is for an update of a previous systematic review, identify as such	n/a

1 Registration

2
3
4 [#2](#) If registered, provide the name of the registry (such as 2
5 PROSPERO) and registration number
6
7
8

9 Authors

10
11
12
13 Contact [#3a](#) Provide name, institutional affiliation, e-mail address of all 1
14 protocol authors; provide physical mailing address of
15 corresponding author
16
17
18

19
20 Contribution [#3b](#) Describe contributions of protocol authors and identify the 7
21 guarantor of the review
22
23
24

25 Amendments

26
27
28
29 [#4](#) If the protocol represents an amendment of a previously 2
30 completed or published protocol, identify as such and list
31 changes; otherwise, state plan for documenting important
32 protocol amendments
33
34
35
36
37

38 Support

39
40
41
42 Sources [#5a](#) Indicate sources of financial or other support for the review 7
43
44

45 Sponsor [#5b](#) Provide name for the review funder and / or sponsor 7
46
47

48 Role of sponsor or [#5c](#) Describe roles of funder(s), sponsor(s), and / or institution(s), 7
49 funder if any, in developing the protocol
50
51
52

53 Introduction

54
55
56 Rationale [#6](#) Describe the rationale for the review in the context of what is 2,3
57
58
59

1		already known	
2			
3			
4	Objectives	#7 Provide an explicit statement of the question(s) the review will	3,4
5		address with reference to participants, interventions,	
6		comparators, and outcomes (PICO)	
7			
8			
9			
10			
11	Methods		
12			
13			
14	Eligibility criteria	#8 Specify the study characteristics (such as PICO, study design,	3,4
15		setting, time frame) and report characteristics (such as years	
16		considered, language, publication status) to be used as	
17		criteria for eligibility for the review	
18			
19			
20			
21			
22			
23			
24	Information	#9 Describe all intended information sources (such as electronic	4
25		databases, contact with study authors, trial registers or other	
26	sources	grey literature sources) with planned dates of coverage	
27			
28			
29			
30			
31			
32	Search strategy	#10 Present draft of search strategy to be used for at least one	4
33		electronic database, including planned limits, such that it	
34		could be repeated	
35			
36			
37			
38			
39	Study records -	#11a Describe the mechanism(s) that will be used to manage	5
40		records and data throughout the review	
41	data management		
42			
43			
44			
45	Study records -	#11b State the process that will be used for selecting studies (such	5
46		as two independent reviewers) through each phase of the	
47	selection process	review (that is, screening, eligibility and inclusion in meta-	
48		analysis)	
49			
50			
51			
52			
53			
54	Study records -	#11c Describe planned method of extracting data from reports	5
55		(such as piloting forms, done independently, in duplicate), any	
56	data collection		
57			
58			
59			
60			

1	process		processes for obtaining and confirming data from investigators	
2				
3				
4	Data items	#12	List and define all variables for which data will be sought	3,4
5			(such as PICO items, funding sources), any pre-planned data	
6			assumptions and simplifications	
7				
8				
9				
10				
11	Outcomes and	#13	List and define all outcomes for which data will be sought,	3,4
12				
13	prioritization		including prioritization of main and additional outcomes, with	
14			rationale	
15				
16				
17				
18				
19	Risk of bias in	#14	Describe anticipated methods for assessing risk of bias of	6
20				
21	individual studies		individual studies, including whether this will be done at the	
22			outcome or study level, or both; state how this information will	
23			be used in data synthesis	
24				
25				
26				
27				
28				
29	Data synthesis	#15a	Describe criteria under which study data will be quantitatively	6
30			synthesised	
31				
32				
33				
34	Data synthesis	#15b	If data are appropriate for quantitative synthesis, describe	6
35			planned summary measures, methods of handling data and	
36			methods of combining data from studies, including any	
37			planned exploration of consistency (such as I ² , Kendall's τ)	
38				
39				
40				
41				
42				
43				
44	Data synthesis	#15c	Describe any proposed additional analyses (such as	6
45			sensitivity or subgroup analyses, meta-regression)	
46				
47				
48				
49	Data synthesis	#15d	If quantitative synthesis is not appropriate, describe the type	6
50			of summary planned	
51				
52				
53				
54	Meta-bias(es)	#16	Specify any planned assessment of meta-bias(es) (such as	6
55			publication bias across studies, selective reporting within	
56				
57				
58				
59				
60				

studies)

Confidence in [#17](#) Describe how the strength of the body of evidence will be
cumulative assessed (such as GRADE)
evidence

6

The PRISMA-P elaboration and explanation paper is distributed under the terms of the Creative Commons Attribution License CC-BY. This checklist was completed on 12. October 2022 using <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)

BMJ Open

Efficacy of carbapenems versus alternative antimicrobials for treating complicated urinary tract infections caused by antimicrobial-resistant Gram-negative bacteria: Protocol for a systematic review and meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-069166.R2
Article Type:	Protocol
Date Submitted by the Author:	23-Mar-2023
Complete List of Authors:	Maeda, Masayuki; Showa University, Department of Clinical Pharmacy Hasegawa, Takeshi; Showa University Noma, Hisashi; The Institute of Statistical Mathematics, Department of Data Science Ota, Erika; St Luke's International University; Tokyo Foundation for Policy Research
Primary Subject Heading:	Infectious diseases
Secondary Subject Heading:	Urology
Keywords:	Urinary tract infections < UROLOGY, INFECTIOUS DISEASES, Pyelonephritis < NEPHROLOGY

SCHOLARONE™
Manuscripts

1
2
3
4
5
6 Efficacy of carbapenems versus alternative antimicrobials for treating complicated
7 urinary tract infections caused by antimicrobial-resistant Gram-negative bacteria:
8 Protocol for a systematic review and meta-analysis
9

10
11 Masayuki Maeda^{1*}, Takeshi Hasegawa², Hisashi Noma³, Erika Ota^{4,5}
12
13

14
15 1 Division of Infection Control Sciences, Department of Clinical Pharmacy, School of
16 Pharmacy, Showa University, Tokyo, Japan; m-maeda@pharm.showa-u.ac.jp

17
18 2 Showa University Research Administration Center, Showa University, Tokyo, Japan;
19 tahasegawa@med.showa-u.ac.jp

20
21 3 Department of Data Science, The Institute of Statistical Mathematics, Tokyo, Japan;
22 noma@ism.ac.jp

23
24 4 Global Health Nursing, Graduate School of Nursing Science, St. Luke's International
25 University, Tokyo, Japan; ota@slcn.ac.jp

26
27 5 The Tokyo Foundation for Policy Research, Tokyo, Japan
28

29
30 *Corresponding author: m-maeda@pharm.showa-u.ac.jp
31

32 **ABSTRACT**

33 **Introduction**

34
35 Complicated urinary tract infections (cUTIs) are associated with poor prognosis. The
36 widespread infection of multidrug-resistant Gram-negative uropathogens such as
37 extended-spectrum beta-lactamase (ESBL)-producing bacteria has limited the efficacy of
38 antibiotics used for treating cUTI. Considering the existence of antimicrobial-resistant
39 (AMR) uropathogens, carbapenem is the last-resort antibiotic for cUTI. Given that
40 carbapenem overuse has facilitated the spread of carbapenem-resistant Gram-negative
41 bacteria, carbapenem dependence should be urgently reduced. However, improvement on
42 the clinical outcomes of alternative antibiotics against cUTI caused by AMR
43 uropathogens has not yet been systematically evaluated. Thus, this systematic review and
44 meta-analysis aims to explore and compare the clinical outcomes of cUTI caused by AMR
45 uropathogens between carbapenem and noncarbapenem antibiotics.
46
47
48
49
50
51

52 **Methods and analysis**

53
54 The study inclusion criteria will be considered based on the PICO model consisting the
55 following elements; population: adult patients with cUTIs caused by Gram-negative
56 uropathogens; intervention: noncarbapenem class of antimicrobial agents with in vitro
57 activities against Gram-negative uropathogens; comparison: treatment of carbapenem
58
59
60

1
2
3
4
5
6 class antibiotics; outcome: a clinical and microbiologic cure. Relevant articles published
7 until December 2022 will be systematically searched in February 2023, using electronic
8 databases such as PubMed, the Cochrane Library, EMBASE, and ClinicalTrials.gov. Two
9 independent reviewers will screen the select literature and then assess the full-text article
10 to meet the inclusion criteria. The risk of bias will be assessed using the Cochrane risk-
11 of-bias assessment tool. The treatment effects of antibiotics will be estimated as a risk
12 ratio with a 95% confidence interval, using the random-effects model.
13
14
15

16 **Ethics and dissemination**

17 This protocol and systematic review will not include direct patient data; thus, informed
18 consent will be waived. The results of this study will be published in an international
19 peer-reviewed journal for wider information dissemination.
20
21

22 **PROSPERO registration number:** CRD42022356064

23 **Keywords:** complicated urinary tract infection, carbapenem, antimicrobial resistant
24
25

26
27 Word Count: 1418
28
29

30 **Strengths and limitations of this study**

31 This new protocol will only include randomised controlled trials and endeavor to
32 address a gap in the current evidence by focusing on complicated urinary tract infections
33 caused by antimicrobial-resistant uropathogens.
34
35

36 The protocol method is conducted robustly in accordance with the Cochrane Handbook
37 for Systematic Reviews.
38

39 Given that the inclusion criteria will include articles published and uploaded to the
40 database, studies such as those in conference presentations and not written in English may
41 be missed.
42
43

44 **INTRODUCTION**

45 Complicated urinary tract infections (cUTIs) are associated with morbidity, mortality,
46 and excessive healthcare costs.¹⁻⁴ Guidelines for cUTIs recommend that the empirical
47 treatment should target Gram-negative uropathogens, including *Escherichia coli*,
48 *Klebsiella pneumoniae*, and non-Enterobacterales. Therefore, broad-spectrum
49 antibiotics are frequently selected for empirical treatment.⁵
50
51
52

53 Over the past few decades, the widespread use of multidrug-resistant Gram-negative
54 bacteria have been limiting the efficacy of antibiotics in cUTI treatment.⁶ In particular,
55 the burden of a disease caused by extended-spectrum beta-lactamase (ESBL)-producing
56
57
58
59
60

1
2
3
4
5
6 bacteria, which have become resistant to almost all beta-lactam antibiotics, is alarming.⁷
7 Carbapenems as a representative of beta-lactam antibiotics exhibit an in vitro activity
8 against most of the Gram-negative bacteria, including AMR uropathogens such as the
9 ESBL-producing bacteria. In fact, carbapenem is the last-resort antibiotic for cUTI
10 caused by antimicrobial-resistant (AMR) uropathogens, including ESBL-producing *E.*
11 *coli* and *K. pneumoniae*.⁸ Consequently, carbapenems have been increasingly used, but
12 their widespread use has facilitated the proliferation of carbapenem-resistant Gram-
13 negative bacteria.⁹ The global spread of carbapenem-resistant bacteria reinforces the
14 urgent need to reduce carbapenem dependence. An important strategy to reduce
15 carbapenem overuse is to evaluate alternative antibiotics.¹⁰ Several systematic reviews
16 and meta-analyses were conducted to evaluate and compare the efficacy between
17 carbapenems and alternative antibiotics for the treatment of cUTIs.¹¹⁻¹⁴ The study results
18 consistently indicated that the efficacy of alternative antibiotics was noninferior to that
19 of carbapenem in patients with cUTIs. Nevertheless, the population of these meta-
20 analyses included both resistant and nonresistant strains. Considering that various
21 antibiotics can treat cUTI caused by nonresistant bacteria, focusing on resistant bacteria
22 is needed to evaluate the efficacy of carbapenem and its alternative antibiotics.
23 Presently, specific data on the efficacy of alternative antibiotics for cUTIs caused by
24 AMR uropathogens remain unavailable. In addition, improvement of the clinical
25 outcomes of patients taking alternative antibiotics for cUTI caused by AMR
26 uropathogens has not yet been systematically evaluated. Thus, we would like to conduct
27 a systematic review and meta-analysis of the clinical outcomes of cUTI caused by AMR
28 uropathogens between carbapenem and noncarbapenem antibiotics. Our meta-analysis
29 will provide useful information for the proper selection of antibiotics used for treating
30 cUTI in a clinical setting, as well as a future direction for the development of alternative
31 antibiotics for AMR cUTI.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 **METHODS AND ANALYSIS**

52 This protocol adheres to the Preferred Reporting Items for Systematic review and Meta-
53 Analysis Protocols (PRISMA-P) guidelines. We prepared this protocol manuscript
54 according to the PRISMA-P checklist.^{15,16}
55
56
57
58
59
60

Population

For the study population, we will include adult patients with cUTIs, including acute pyelonephritis, caused by Gram-negative uropathogens that are resistant to third-generation cephalosporin.¹⁷

Interventions

The intervention involves the noncarbapenem class of antimicrobial agents with in vitro activities against Gram-negative uropathogens that are resistant to third-generation cephalosporin.

Controls

The control is the treatment of carbapenem class antibiotics.

Outcomes

The primary outcome will be the composite outcome of clinical and microbiologic cure defined by the US Food and Drug Administration as follows: resolution of cUTI symptoms present at trial entry (and no new symptoms) and the reduction of bacterial pathogens found at trial entry to fewer than 10^3 CFU/mL on urine culture.¹⁸ The secondary outcomes will be the microbiologic outcome responses and death at each endpoint.

Study designs

This review will only include individual and cluster randomized controlled trials.

Search strategy

Literature published until December 2022 will be searched in February 2023 in the following databases: MEDLINE/PubMed, the Cochrane Library (Cochrane Central Register of Controlled Trials, CENTRAL), EMBASE, and ClinicalTrials.gov. The comprehensive search strategies will use the developed search terms shown in Table 1 and Supplemental File 1.

Table 1 Comprehensive search strategy methods for Medline/PubMed

No.	Search queries
#1	Urinary Tract Infections[mh] OR "urinary tract infection*" [tiab] OR cUTI* [tiab] OR Pyelonephritis[mh] OR pyelonephritis* [tiab]
#2	Drug Resistance[mh] OR resistan* [tiab]
#3	Carbapenems[mh] OR carbapenem* [tw] OR CS-533[tw] OR CS533[tw] OR Imipenem[mh] OR imipenem* [tw] OR MK-0787[tw] OR MK0787[tw] OR N-Formimidoylthienamycin[tw] OR doripenem* [tw] OR "S 4661" [tw] OR S4661[tw] OR ertapenem* [tw] OR invanz[tw] OR panipenem* [tw] OR meropenem* [tw] OR merrem[tw] OR penem[tw] OR ronem[tw] OR SM-7338[tw] OR SM7338[tw] OR biapenem* [tw] OR L-627[tw] OR L627[tw] OR LJC-10627[tw] OR LJC10627[tw]
#4	#1 AND #2 AND #3
#5	(controlled clinical trial[pt] OR randomized [tiab] OR randomised [tiab] OR randomly [tiab] OR clinical trials as topic [mesh:noexp] OR trial [ti] OR placebo [tiab]) NOT (Animals [mh] NOT Humans [mh])
#6	#4 AND #5
#7	Sepsis [mh] OR sepsis* [tiab] OR "blood poisoning*" [tiab] OR "bloodstream Infect*" [tiab] OR pyaemi* [tiab] OR pyemi* [tiab] OR pyohemi* [tiab] OR pyohaemi* [tiab] OR septicemi* [tiab] OR "bloodstream infection*" [tiab] OR bacteremi* [tiab] OR bacteraemi* [tiab]
#8	#6 AND #7

Screening of the retrieved articles

Two independent researchers will screen the retrieved articles. The title and abstract will be screened and scrutinized to meet the study criteria, using the online software Rayyan, which helps to conduct systematic reviews.¹⁹ Two researchers will independently review the full-text manuscripts according to the eligibility criteria for this review. If they differ in the decision on whether or not the study meets the inclusion criteria, another reviewer will resolve the conflicts.

Data extraction

The selected data will be extracted by two independent researchers using Microsoft Excel, conforming to guidelines of the Cochrane Handbook for Systematic Reviews.²⁰ The following data will be extracted from the selected studies: author names, publication year,

1
2
3
4
5
6 study population, baseline characteristics, study settings, intervention details, outcomes,
7 and subgroup analysis stratified by AMR pathogens.
8
9

10 **Assessment of risk of bias**

11 Two independent researchers will assess the risk of bias using the Cochrane risk-of-bias
12 assessment tool. The assessment domain consists of the following: random sequence
13 generation (selection bias), allocation concealment (selection bias), blinding of
14 participants and personnel (performance bias), blinding of outcome assessment of self-
15 reported outcomes and reaction time (detection bias), incomplete outcome data (attrition
16 bias), selective reporting (reporting bias), and other biases, such as imbalance of baseline
17 characteristics and overdiagnosis bias.²¹ The included studies will be divided into low
18 risk, high risk, and unclear risk according to the reviewers' judgment. Any discord will
19 be resolved through a discussion between them.
20
21
22
23
24
25

26 **Data analysis**

27 For dichotomous data, the treatment effects will be estimated as a risk ratio with a 95%
28 confidence interval, using the random effects model. We will use the random-effects
29 model to address the possible between-studies heterogeneity. We cannot assess how
30 statistical heterogeneity exists before seeing the datasets; thus, we will adopt the random-
31 effect model for the primary statistical analyses. Heterogeneity will be assessed using the
32 chi-square test and I^2 statistics. The heterogeneity will be addressed through meta-
33 regression and subgroup analyses. We will conduct a sensitivity analysis to determine the
34 impact of the exclusion of studies at an overall high risk of bias and outliers for the
35 primary outcome. Publication bias will be assessed in forest plots using Egger's test.
36 Forest plots and funnel plots will be generated using the Review Manager (RevMan)
37 software. We will perform the synthesis analyses when at least four studies are eligible.
38 After the preliminary assessments of publication biases, we will perform the meta-
39 analyses if there are no serious systematic biases. We will present summary data and
40 assess individual studies in detail if a meta-analysis is not feasible.²⁰
41
42
43
44
45
46
47
48
49

50 **Grading of evidence**

51 The strength of the body of evidence will be assessed by two independent researchers
52 using the Grading of Recommendations, Assessment, Development and Evaluations
53 (GRADE) to judge the quality of evidence for outcomes.²² GRADE will then be assessed
54 according to the risk of bias among studies, inconsistency, imprecision, indirectness, and
55 publication bias. We will generate a summary of the findings table using the GRADEpro
56
57
58
59
60

software.

Patient and public involvement

No patients or citizens will be involved in this research. Only data that are already published will be used. For this systematic review, the estimation of the efficacy of the treatment will benefit patients with cUTI.

ETHICS AND DISSEMINATION

This systematic review and meta-analysis will not include direct patient data because it will only use studies that are already published. Therefore, informed consent will be waived. The results of this study will be published in an international peer-reviewed journal for wider information dissemination. This work will influence the national guidelines for the treatment of cUTIs.¹⁷

Contributorship statement:

Conception of the study: MM. Statistical concept: TH, HN, and EO. Construction of search strategy: MM. Drafting manuscript: MM and TH. Review and finalization: TH, HN, and EO. All authors reviewed and approved the final version of the manuscript. Guarantor of the review: MM.

Funding statement:

This work was supported by JSPS KAKENHI Grant Number 19K03092.

Competing interests statement

None declared.

Patient consent for publication

Not applicable

Provenance and peer review

Not commissioned; externally peer reviewed.

REFERENCES

1. Nicolle LE; AMMI Canada Guidelines Committee. Complicated urinary tract infection in adults. *Can J Infect Dis Med Microbiol.* 2005;16(6):349.

- 1
2
3
4
5
6 2. Wagenlehner FME, Bjerklund Johansen TE, Cai T, Koves B, Kranz J, Pilatz A,
7 Tandogdu Z. Epidemiology, definition and treatment of complicated urinary tract
8 infections. *Nat Rev Urol*. 2020;17(10):586.
- 9
10
11 3. Brown P, Ki M, Foxman B. Acute pyelonephritis among adults: cost of illness and
12 considerations for the economic evaluation of therapy. *Pharmacoeconomics*.
13 2005;23(11):1123.
- 14
15
16 4. Neal DE Jr. Complicated urinary tract infections. *Urol Clin North Am*. 2008;35(1):13.
- 17
18 5. Hooton TM, Bradley SF, Cardenas DD, Colgan R, Geerlings SE, Rice JC, Saint S,
19 Schaeffer AJ, Tambayh PA, Tenke P, Nicolle LE; Infectious Diseases Society of
20 America. Diagnosis, prevention, and treatment of catheter-associated urinary tract
21 infection in adults: 2009 International Clinical Practice Guidelines from the
22 Infectious Diseases Society of America. *Clin Infect Dis*. 2010;50(5):625.
- 23
24
25 6. World Health Organization. Antimicrobial resistance. Available from:
26 <https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance>.
27 Accessed June 6, 2022.
- 28
29
30 7. Bezabih YM, Bezabih A, Dion M, Batard E, Teka S, Obole A, Dessalegn N, Enyew
31 A, Roujeinikova A, Alamneh E, Mirkazemi C, Peterson GM, Bezabhe WM.
32 Comparison of the global prevalence and trend of human intestinal carriage of ESBL-
33 producing *Escherichia coli* between healthcare and community settings: a systematic
34 review and meta-analysis. *JAC Antimicrob Resist*. 2022;4(3):dlac048.
- 35
36
37 8. Paterson DL, Henderson A, Harris PNA. Current evidence for therapy of ceftriaxone-
38 resistant Gram-negative bacteremia. *Curr Opin Infect Dis*. 2020;33(1):78.
- 39
40
41 9. European Centre for Disease Prevention and Control. Carbapenem-resistant
42 *Enterobacteriaceae* (CRE). Available from:
43 [https://www.ecdc.europa.eu/en/publications-data/directory-guidance-prevention-](https://www.ecdc.europa.eu/en/publications-data/directory-guidance-prevention-and-control/prevention-and-control-infections-1)
44 [and-control/prevention-and-control-infections-1](https://www.ecdc.europa.eu/en/publications-data/directory-guidance-prevention-and-control/prevention-and-control-infections-1). Accessed June 6, 2022.
- 45
46
47 10. Wilson APR. Sparing carbapenem usage. *J Antimicrob Chemother*. 2017;72(9):2410.
- 48
49
50 11. Singh KP, Li G, Mitrani-Gold FS, Kurtinecz M, Wetherington J, Tomayko JF,
51 Mundy LM. Systematic review and meta-analysis of antimicrobial treatment effect
52 estimation in complicated urinary tract infection. *Antimicrob Agents Chemother*.
53 2013;57(11):5284.
- 54
55
56
57
58
59
60

12. Ten Doesschate T, van der Vaart TW, Damen JAA, Bonten MJM, van Werkhoven CH. Carbapenem-alternative strategies for complicated urinary tract infections: A systematic review of randomized controlled trials. *J Infect.* 2020;81(4):499.
13. Isler B, Ezure Y, Romero JLG, Harris P, Stewart AG, Paterson DL. Is ceftazidime/avibactam an option for serious infections due to extended-spectrum- β -lactamase- and AmpC-producing enterobacteriales?: A systematic review and meta-analysis. *Antimicrob Agents Chemother.* 2020;65(1):e01052-20.
14. Ezure Y, Rico V, Paterson DL, Hall L, Harris PNA, Soriano A, Roberts JA, Bassetti M, Roberts MJ, Righi E, Wright H. Efficacy and safety of carbapenems vs new antibiotics for treatment of adult patients with complicated urinary tract infections: A systematic review and meta-analysis. *Open Forum Infect Dis.* 2022;9(5):ofaa480.
15. Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA; PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ.* 2015;350:g7647.
16. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ.* 2021;372:n71.
17. Infectious Diseases Society of America. IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections: Version 1.0. Available: <https://www.idsociety.org/practice-guideline/amr-guidance/>
18. U.S. Food & Drug Administration. Complicated urinary tract infections: developing drugs for treatment. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Available: <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/complicated-urinary-tract-infections-developing-drugs-treatment>
19. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. *Syst Rev.* 2016;5(1):210.

- 1
2
3
4
5
6 20. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors).
7 Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated
8 February 2022). Cochrane, 2022. Available from
9 www.training.cochrane.org/handbook.
10
11
12
13 21. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, Norris S, Falck-Ytter Y,
14 Glasziou P, DeBeer H, Jaeschke R, Rind D, Meerpohl J, Dahm P, Schünemann HJ.
15 GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of
16 findings tables. *J Clin Epidemiol*. 2011;64(4):383
17
18
19 22. Schünemann HJ, Higgins JPT, Vist GE, Glasziou P, Akl EA, Skoetz N, Guyatt GH.
20 Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of
21 the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ,
22 Welch VA (editors). *Cochrane Handbook for Systematic Reviews of Interventions*
23 version 6.3 (updated February 2022). Cochrane, 2022. Available from
24 www.training.cochrane.org/handbook.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supplemental material - bmjopen-2022-069166

Table 1 Comprehensive search strategy methods for Cochrane Library (Cochrane Central Register of Controlled Trials, CENTRAL)

No.	Search queries
#1	[mh "Urinary Tract Infections"] OR [mh Pyelonephritis] OR ((urinary NEXT tract NEXT infection*) OR cUTI* OR APEKS-cUTI* OR pyelonephritis*):ti,ab,kw
#2	[mh "Drug Resistance"] OR resistan*:ti,ab,kw
#3	[mh Carbapenems] OR [mh Imipenem] OR (carbapenem* OR CS?533 OR imipenem* OR MK?0787 OR N-Formimidoylthienamycin OR doripenem* OR S?4661 OR ertapenem* OR invanz OR panipenem* OR meropenem* OR merrem OR penem OR ronem OR SM?7338 OR biapenem* OR L?627 OR LJC?10627 OR CLI?86815):ti,ab,kw
#4	#1 AND #2 AND #3
#5	[mh sepsis] OR (sepsis* OR (blood NEXT poisoning*) OR (bloodstream NEXT Infect*) OR pyaemi* OR pyemi* OR pyohemi* OR pyohaemi* OR septicemi* OR (bloodstream NEXT infection*) OR bacteremi* OR bacteraemi* OR (blood NEXT stream NEXT Infect*)):ti,ab,kw
#6	#4 AND #5

Table 2 Comprehensive search strategy methods for EMBASE.

No.	Search queries
#1	'urinary tract infection'/exp OR 'urinary tract infection' OR cuti* OR 'pyelonephritis'/exp OR pyelonephritis
#2	'drug resistance'/exp OR 'drug resistance' OR 'resistance'/exp OR resistance
#3	'carbapenems'/exp OR carbapenems OR 'cs 533'/exp OR 'cs 533' OR 'cs533'/exp OR cs533 OR 'panipenem'/exp OR panipenem OR 'imipenem'/exp OR imipenem OR 'mk 0787'/exp OR 'mk 0787' OR mk0787 OR 'n formimidoylthienamycin'/exp OR 'n formimidoylthienamycin' OR 'doripenem'/exp OR doripenem OR 's 4661'/exp OR 's 4661' OR 's4661'/exp OR s4661 OR 'ertapenem'/exp OR ertapenem OR 'invanz'/exp OR invanz OR 'meropenem'/exp OR meropenem OR 'merrem'/exp OR merrem OR penem OR ronem OR 'sm 7338'/exp OR 'sm 7338' OR 'sm7338'/exp OR sm7338 OR 'biapenem'/exp OR biapenem OR 'l 627'/exp OR 'l 627' OR 'l627'/exp OR l627 OR 'ljc 10627'/exp OR 'ljc 10627' OR 'ljc10627'/exp OR ljc10627

#4	#1 AND #2 AND #3
#5	'clinical trial'/de OR 'randomized controlled trial'/de OR 'randomization'/de OR 'single blind procedure'/de OR 'double blind procedure'/de OR 'crossover procedure'/de OR 'placebo'/de OR 'prospective study'/de OR ('randomi?ed controlled' NEXT/1 trial*) OR rct OR 'randomly allocated' OR 'allocated randomly' OR 'random allocation' OR (allocated NEAR/2 random) OR (single NEXT/1 blind*) OR (double NEXT/1 blind*) OR ((treble OR triple) NEAR/1 blind*) OR placebo*
#6	#4 AND #5
#7	'sepsis'/exp OR sepsis OR 'blood poisoning' OR 'bloodstream infection'/exp OR 'bloodstream infection' OR 'pyemia'/exp OR pyemia OR 'pyohemia'/exp OR pyohemia OR 'septicemia'/exp OR septicemia OR 'bacteremia'/exp OR bacteremia OR 'bacteraemia'/exp OR bacteraemia
#8	#6 AND #7

Table 3 Comprehensive search strategy methods for ClinicalTrials.gov.

Search fields	Search queries
Condition or disease	("Urinary Tract Infections" OR Bacteriuria OR Pyuria OR cUTI OR Pyelonephritis)
Other terms	(resistant OR resistance)
Intervention/treatment	(carbapenem OR doripenem OR ertapenem OR Imipenem OR doripenem OR ertapenem OR meropenem OR biapenem)

Reporting checklist for protocol of a systematic review and meta analysis.

Based on the PRISMA-P guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the PRISMA-Reporting guidelines, and cite them as:

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.

			Page Number
Title			
Identification	#1a	Identify the report as a protocol of a systematic review	1
Update	#1b	If the protocol is for an update of a previous systematic review, identify as such	n/a

1 Registration

2
3
4 [#2](#) If registered, provide the name of the registry (such as 2
5 PROSPERO) and registration number
6
7
8

9 Authors

10
11
12
13 Contact [#3a](#) Provide name, institutional affiliation, e-mail address of all 1
14 protocol authors; provide physical mailing address of
15 corresponding author
16
17
18

19
20 Contribution [#3b](#) Describe contributions of protocol authors and identify the 7
21 guarantor of the review
22
23
24

25 Amendments

26
27
28
29 [#4](#) If the protocol represents an amendment of a previously 2
30 completed or published protocol, identify as such and list
31 changes; otherwise, state plan for documenting important
32 protocol amendments
33
34
35
36
37

38 Support

39
40
41
42 Sources [#5a](#) Indicate sources of financial or other support for the review 7
43
44

45 Sponsor [#5b](#) Provide name for the review funder and / or sponsor 7
46
47

48 Role of sponsor or [#5c](#) Describe roles of funder(s), sponsor(s), and / or institution(s), 7
49 funder if any, in developing the protocol
50
51
52

53 Introduction

54
55
56 Rationale [#6](#) Describe the rationale for the review in the context of what is 2,3
57
58
59

1		already known	
2			
3			
4	Objectives	#7 Provide an explicit statement of the question(s) the review will	3,4
5		address with reference to participants, interventions,	
6		comparators, and outcomes (PICO)	
7			
8			
9			
10			
11	Methods		
12			
13			
14	Eligibility criteria	#8 Specify the study characteristics (such as PICO, study design,	3,4
15		setting, time frame) and report characteristics (such as years	
16		considered, language, publication status) to be used as	
17		criteria for eligibility for the review	
18			
19			
20			
21			
22			
23			
24	Information	#9 Describe all intended information sources (such as electronic	4
25		databases, contact with study authors, trial registers or other	
26	sources	grey literature sources) with planned dates of coverage	
27			
28			
29			
30			
31			
32	Search strategy	#10 Present draft of search strategy to be used for at least one	4
33		electronic database, including planned limits, such that it	
34		could be repeated	
35			
36			
37			
38			
39	Study records -	#11a Describe the mechanism(s) that will be used to manage	5
40		records and data throughout the review	
41	data management		
42			
43			
44			
45	Study records -	#11b State the process that will be used for selecting studies (such	5
46		as two independent reviewers) through each phase of the	
47	selection process	review (that is, screening, eligibility and inclusion in meta-	
48		analysis)	
49			
50			
51			
52			
53			
54	Study records -	#11c Describe planned method of extracting data from reports	5
55		(such as piloting forms, done independently, in duplicate), any	
56	data collection		
57			
58			
59			
60			

1	process		processes for obtaining and confirming data from investigators	
2				
3				
4	Data items	#12	List and define all variables for which data will be sought	3,4
5			(such as PICO items, funding sources), any pre-planned data	
6			assumptions and simplifications	
7				
8				
9				
10				
11	Outcomes and	#13	List and define all outcomes for which data will be sought,	3,4
12				
13	prioritization		including prioritization of main and additional outcomes, with	
14			rationale	
15				
16				
17				
18				
19	Risk of bias in	#14	Describe anticipated methods for assessing risk of bias of	6
20				
21	individual studies		individual studies, including whether this will be done at the	
22			outcome or study level, or both; state how this information will	
23			be used in data synthesis	
24				
25				
26				
27				
28				
29	Data synthesis	#15a	Describe criteria under which study data will be quantitatively	6
30			synthesised	
31				
32				
33				
34	Data synthesis	#15b	If data are appropriate for quantitative synthesis, describe	6
35			planned summary measures, methods of handling data and	
36			methods of combining data from studies, including any	
37			planned exploration of consistency (such as I ² , Kendall's τ)	
38				
39				
40				
41				
42				
43				
44	Data synthesis	#15c	Describe any proposed additional analyses (such as	6
45			sensitivity or subgroup analyses, meta-regression)	
46				
47				
48				
49	Data synthesis	#15d	If quantitative synthesis is not appropriate, describe the type	6
50			of summary planned	
51				
52				
53				
54	Meta-bias(es)	#16	Specify any planned assessment of meta-bias(es) (such as	6
55			publication bias across studies, selective reporting within	
56				
57				
58				
59				
60				

studies)

Confidence in [#17](#) Describe how the strength of the body of evidence will be
cumulative assessed (such as GRADE)
evidence

6

The PRISMA-P elaboration and explanation paper is distributed under the terms of the Creative Commons Attribution License CC-BY. This checklist was completed on 12. October 2022 using <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)